Background <p>Neutralization of interferon (IFN)- abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-. Inducible tumor-specific MHC class II (tsMHC-II) underlies responsiveness to anti-PD-(L)1. Retrospective studies show that tsMHC-II positivity associates with improved outcomes in patients treated…
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Journal for ImmunoTherapy of Cancer | | Middleton, G., Gaskell, C., Savage, J., Bridgewater, J., Ross, P., Saunders, M., Palmer, D., Plummer, R., Clive, S., Coyle, V., Thomas, A., Cunningham, D., Taniere, P., Billingham, L.
Topics: colorectal-cancer, blood-cancer, immunotherapy, targeted-therapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer